公开(公告)号：US10513501B2

公开(公告)日：2019-12-24

申请号：US16218122

申请日：2018-12-12

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  David S. Millan ,  Matthew W. Martin ,  Kenneth W. Bair

IPC: A61K31/513 ,  C07D243/14 ,  C07D401/06 ,  C07D403/06 ,  C07D401/10 ,  C07D403/10 ,  C07D413/06 ,  C07D417/06 ,  C07D267/14 ,  C07D413/12 ,  C07D413/04 ,  C07D291/08 ,  C07D405/06 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D498/08 ,  C07D493/08 ,  C07D413/08 ,  C07D491/107 ,  C07D495/10 ,  C07D267/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US10472371B2

公开(公告)日：2019-11-12

申请号：US16245654

申请日：2019-01-11

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, Jr. ,  Lorna Mitchell ,  Tatiana Shelekhin

IPC: C07D487/04 ,  C07D519/00 ,  A61P7/00 ,  A61K9/00 ,  A61K31/407

Abstract: Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).

公开(公告)号：US10472342B2

公开(公告)日：2019-11-12

申请号：US16383296

申请日：2019-04-12

Applicant: FORMA Therapeutics, Inc.

Inventor： Kenneth W. Bair ,  David R. Lancia, Jr. ,  Hongbin Li ,  James Loch ,  Wei Lu ,  Matthew W. Martin ,  David S. Millan ,  Shawn E. R. Schiller ,  Mark J. Tebbe

IPC: C07D295/192 ,  A61K31/4965 ,  A61P35/00 ,  C07D401/04 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D213/65 ,  C07D213/69 ,  C07D213/56 ,  C07D231/12 ,  C07D235/08 ,  C07D209/08 ,  C07D209/18 ,  C07D263/57 ,  C07D277/66 ,  C07D277/62 ,  C07D271/12 ,  C07D513/04 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K45/06 ,  C07D217/16 ,  A61K31/5025 ,  A61K31/506 ,  C07D305/08 ,  C07D257/04 ,  C07D417/12 ,  C07D231/56 ,  C07D215/14

Abstract: The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

公开(公告)号：US10464910B2

公开(公告)日：2019-11-05

申请号：US16219669

申请日：2018-12-13

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Heather Davis ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  Kenneth W. Bair ,  David S. Millan ,  Matthew W. Martin

IPC: A61K31/5513 ,  C07D243/14 ,  C07D267/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/04 ,  C07D291/08 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D498/08 ,  C07D493/08 ,  C07D413/08 ,  C07D491/107 ,  C07D495/10 ,  C07D267/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US10450284B2

公开(公告)日：2019-10-22

申请号：US16220041

申请日：2018-12-14

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  David S. Millan ,  Matthew W. Martin

IPC: A61K31/553 ,  C07D498/04 ,  C07D267/14 ,  C07D413/06 ,  C07D413/12 ,  C07D413/04 ,  C07D243/14 ,  C07D291/08 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D498/08 ,  C07D493/08 ,  C07D413/08 ,  C07D491/107 ,  C07D495/10 ,  C07D267/12

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US10421732B2

公开(公告)日：2019-09-24

申请号：US16219685

申请日：2018-12-13

Applicant: FORMA Therapeutics, Inc.

Inventor： Xiaozhang Zheng ,  Pui Yee Ng ,  Bingsong Han ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Cuixian Liu ,  Heather Davis ,  Aleksandra Rudnitskaya ,  David R. Lancia, Jr. ,  Kenneth W. Bair ,  David S. Millan ,  Matthew W. Martin

IPC: A61K31/553 ,  C07D267/14 ,  C07D413/12 ,  C07D267/12 ,  C07D413/06 ,  C07D401/06 ,  C07D417/04 ,  C07D471/04 ,  C07D498/04 ,  C07D243/14 ,  C07D291/08 ,  C07D498/08 ,  C07D401/10 ,  C07D403/06 ,  C07D403/10 ,  C07D405/06 ,  C07D413/14 ,  C07D495/10 ,  C07D491/107 ,  C07D413/08 ,  C07D493/08 ,  C07D413/04

Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.

公开(公告)号：US10399951B2

公开(公告)日：2019-09-03

申请号：US16119962

申请日：2018-08-31

Applicant: FORMA Therapeutics, Inc.

Inventor： Kenneth W. Bair ,  David R. Lancia, Jr. ,  Hongbin Li ,  James Loch ,  Wei Lu ,  Matthew W. Martin ,  David S. Millan ,  Shawn E. R. Schiller ,  Mark J. Tebbe

IPC: C07D295/192 ,  A61K31/4965 ,  A61P35/00 ,  C07D401/04 ,  C07D403/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D213/65 ,  C07D213/69 ,  C07D213/56 ,  C07D231/12 ,  C07D235/08 ,  C07D209/08 ,  C07D209/18 ,  C07D263/57 ,  C07D271/12 ,  C07D277/66 ,  C07D277/62 ,  C07D513/04 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/4985 ,  A61K45/06 ,  C07D215/14 ,  C07D231/56 ,  C07D257/04 ,  C07D487/04 ,  C07D305/08 ,  A61K31/5025 ,  A61K31/506 ,  C07D217/16

Abstract: The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.

公开(公告)号：US09840491B2

公开(公告)日：2017-12-12

申请号：US15015571

申请日：2016-02-04

Applicant: Forma Therapeutics, Inc.

Inventor： Stephanos Ioannidis ,  Adam Charles Talbot ,  Bruce Follows ,  Alexandre Joseph Buckmelter ,  Minghua Wang ,  Ann-Marie Campbell ,  David R. Lancia, Jr.

IPC: C07D401/06 ,  C07D239/88 ,  C07D487/04 ,  C07D471/04

CPC classification number: C07D401/06 ,  C07D239/88 ,  C07D471/04 ,  C07D487/04

Abstract: The present disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R4′, X1, Y1, Y2, Y3, Y4, n, and m are described herein.

公开(公告)号：US20140163004A1

公开(公告)日：2014-06-12

申请号：US13949508

申请日：2013-07-24

Applicant: Forma Therapeutics, Inc.

Inventor： KRISHNA MURTHI ,  REBECCA CASAUBON ,  ARTHUR F. KLUGE ,  CHASE SMITH ,  JOACHIM VOGT

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/551 ,  A61K31/519 ,  A61K31/5377

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06

Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.

公开(公告)号：US20140163003A1

公开(公告)日：2014-06-12

申请号：US13949495

申请日：2013-07-24

Applicant: KRISHNA MURTHI ,  REBECCA CASAUBON ,  ARTHUR F. KLUGE ,  CHASE SMITH ,  JOACHIM VOGT

Inventor： KRISHNA MURTHI ,  REBECCA CASAUBON ,  ARTHUR F. KLUGE ,  CHASE SMITH ,  JOACHIM VOGT

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K45/06

Abstract: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.